GELS

distress 3/10 · well-funded / low risk

$0.66-3%today-66% from 52w high

gelteq.com7 employeesFounded 2017Clayton, VICDrug Manufacturers - Specialty & Generic

Revenue

pre-revenue

Liquidity

$0M

Runway

—

Shares 1y

-12%

Price & events

-43.6% over 6M

CatalystRating changeDilutionFinancingdashed = today

-2.8%

+12.1%

-9.8%

-2.5%

-37.1%

-63.9%

—

-77.6%

All

Overview

Market Cap: $6.23M
Enterprise Value: $6.23M
Volume: 27.88K
52 Week Range: $0.39 – $1.95
Total Shares: 9.44M
Float Shares: 5.15M
Short %: 2.36%
% Held by Insiders: 47.53%
% Held by Institutions: 0.58%
RVOL: 0.00x

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 0

No catalyst news yet.

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 9,438,075 · 1 offerings/1y · 0 PIPEs

2025-08-29EFFECTshelf_effective
2025-08-29424B3offering
2025-07-25F-1/Ashelf_registration
2025-07-01F-1shelf_registration
2024-10-22424B4offering
2024-09-30EFFECTshelf_effective
2024-09-25F-1/Ashelf_registration

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors

none identified